Altimmune's Pemvidutide Shows Significant Fibrosis Regression in MASH Phase 2b Data at EASL 2026
Summary
Altimmune announced strong new Phase 2b IMPACT trial data for pemvidutide in MASH at EASL 2026. The data showed concurrent improvements across multiple non-invasive markers and significant qFibrosis-measured fibrosis regression at 24 weeks. Specifically, 68.6% of patients on the 1.2 mg dose and 54.5% on the 1.8 mg dose achieved at least one stage of qFibrosis regression, compared to 29.6% on placebo. This positive clinical update follows recent significant capital raises, including a $225 million public offering in April, which substantially bolstered the company's cash position. Strong Phase 2b data, particularly demonstrating fibrosis regression, is a major de-risking event for pemvidutide, Altimmune's lead drug candidate for MASH, significantly strengthening its commercial potential. The company plans to begin patient enrollment in its PERFORMA Phase 3 trial for pemvidutide in MASH in the second half of this year.
At the time of this announcement, ALT was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $569.8M. The 52-week trading range was $2.56 to $7.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.